公司代碼MRNX
資產類別Equity
基金管理人Defiance
註冊地US
費用率1.34%
成立日期2026-02-03
追蹤指數--
MRNX was created on 2026-02-03 by Defiance. The fund's investment portfolio concentrates primarily on health care equity. MRNX seeks to deliver 2x leveraged exposure to the daily share price movement of Moderna, Inc. (NASDAQ: MRNA), net fees and expenses, through derivatives like swap agreements. MRNA develops mRNA-based vaccines and therapies, best known for its COVID-19 vaccine.